Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025)

Gyre Therapeutics (GYRE) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $9.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability rose 15.66% year-over-year to $9.6 million; the TTM figure through Dec 2025 stood at $9.6 million (up 15.66% YoY), while the FY2025 annual figure was $9.6 million, up 15.66% from the prior year.
• Non-Current Deferred Tax Liability climbed to $9.6 million in Q4 2025 per GYRE's latest filing, from $8.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $9.6 million in Q4 2025 and bottomed at $2.5 million in Q4 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $6.8 million across 3 years, with a median of $8.3 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability surged 232.0% — and 2025, when it climbed 15.66%.
• Gyre Therapeutics' Non-Current Deferred Tax Liability stood at $2.5 million in 2023, then soared by 232.0% to $8.3 million in 2024, then rose by 15.66% to $9.6 million in 2025.
• Business Quant data shows GYRE's Non-Current Deferred Tax Liability at $9.6 million in Q4 2025, $8.3 million in Q4 2024, and $2.5 million in Q4 2023.